Navigation Links
Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
Date:9/8/2013

technology since its performance for this groundbreaking study. The current generation of our technology is capable of producing 50 times more protein per dose, and our R&D team has many new improvements in the making, further increasing the potential of messenger RNA therapeutics™ to transform drug development and improve patients' lives."

Moderna in March announced an exclusive strategic option agreement with AstraZeneca to discover, develop, and commercialize messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic, and renal diseases as well as selected targets in oncology. Targets covered under the agreement included the use of VEGF in the treatment of cardiovascular disease.

"Cardio-metabolic medicine is a core therapy area for AstraZeneca, and part of our research focuses on identifying novel therapies that will activate progenitor cells within the heart to turn into healthy heart cells. Recent findings by Dr. Chien and his team will play an important role in our work with Karolinska Institutet to advance cardiac regenerative therapy and our collaboration with Moderna Therapeutics to discover and develop messenger RNA therapeutics™," said Dr. Marcus Schindler, Head of the AstraZeneca Cardiovascular and Metabolic Disease Innovative Medicines Unit.

About Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including 144 patent applications with 6,910 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
2. ResearchMoz.us: Private Healthcare Market - Investigation, Study, Size, Share in Central Europe and Poland and Poland 2013
3. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
4. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
5. Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
6. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
7. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
8. BioStorage Technologies Launches INTEGRITY Study to Measure Effect of Time, Temperature and Preparation Methods on DNA and RNA Samples
9. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
10. VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
11. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... “We are honored to be named to ... CEO of Radiant Sage. “We are offering truly ground-breaking ... corelab market to a different level. We are ... efficiently and effectively manage the massive amounts of medical ... and read by trained physicians. Being recognized by technology ...
(Date:8/27/2014)... Reportbuyer.com has added a new market ... A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds graphene, ... to water treatment, but is graphene the only ... Graphene Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... Research and Markets has announced ... & Paper Industry Report 2014" report to their ... & Paper Industry Report 2014 is a professional and ... enzyme for pulp & paper industry. The ... definitions, classifications, applications and industry chain structure. The enzyme ...
(Date:8/27/2014)... , Aug. 27, 2014  ARCH Venture Partners, ... investing in the development of seed and early-stage ... venture fund closed with more than $400 million ... $250 million subscription target by more than $150 ... shows the strength and potential of our approach ...
Breaking Biology Technology:Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... Anticipating a catastrophic increase in Alzheimer,s disease and related ... Plan for Alzheimer,s disease, a disease estimated to double ... a 10-year course of action with guiding principles, goals ... crisis.   Alzheimer,s will soon soar to ...
... 2011 GlobalCare Clinical Trials, Ltd, (GlobalCare) today ... selected clinical study visits at convenient locations – ... – for study patients to support phase I-IV ... and personalized medicine in all age groups. GlobalCare,s ...
... Inc. (NYSE Amex: PTN ) announced that it ... Stock Conference on Tuesday, March 15, 2011, at 12:00 p.m. ... Carlton Laguna Niguel in Dana Point, CA. ... Technologies, will provide an update on Palatin,s corporate and development ...
Cached Biology Technology:California Leaders Confront Alarming Rise in Alzheimer's Cases 2California Leaders Confront Alarming Rise in Alzheimer's Cases 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 2GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 4
(Date:8/27/2014)... manipulating neural circuits in the brain of mice, ... memories. The research, led by Howard Hughes Medical ... of Technology (MIT), reveals that the connections between ... information about an experience and the part of ... that experience are malleable. , Altering those ...
(Date:8/27/2014)... based upon a proxy for impact have been identified ... approach to scientific research. , The researchers from the ... top 100 pathogens affecting humans and the top 100 ... will help governments across the continent plan for risks ... a result of climate change, and for biosecurity. , ...
(Date:8/27/2014)... news release is available in German . ... 1A is the most common inherited disease affecting the ... at the Max Planck Institute of Experimental Medicine and ... of Schwann cells is impaired in rats with the ... insulating layer known as myelin, which facilitates the rapid ...
Breaking Biology News(10 mins):Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2
... of researchers has shown that female kittens consume more food ... with entire littermates. This research was conducted at the WALTHAM ... Petcare brands such as WHISKAS and ROYAL CANIN. In ... consumed more food than their entire littermates for an 18 ...
... some strains of algae, when starved of nutrients, quickly build ... discovery lay dormant until people began to search in earnest ... 2000s, algal fuel production enjoyed a tremendous vogue, as scientists ... "pond scum" to oil. But a recent wave of bankruptcies ...
... October 2011, Christian Sonne, Senior Scientist at Aarhus University, defends ... University of Copenhagen. "The accumulated industrial chemicals cause diseases ... immediate deaths. On the other hand, the toxins damage the ... and not least their reproductive systems. However, the harm suffered ...
Cached Biology News:New research from WALTHAM demonstrates the importance of portion control for maintaining healthy body weight in neutered female kittens 2WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 2WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 3WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 4
... SDS and Non-ionic Detergent Removal ... detergent , Very selective, virtually no cross-reactivity ... centrifuge and discard pellet , Economical ... chromatography , Detergents can often interfere with ...
Extracti-Gel D Detergent Removing Gel...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
SDS-OutT SDS Precipitation Reagent...
Biology Products: